165
14.
Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression
to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advance
stage:a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.J
Hepatol.1999;30:653-659.
15.
Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C:
association with reduced hepatocellular carcinoma development and improved
survival. Ann Intern Med. 2005;142:105–114.
16.
Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in
the Child-Pugh class A com-pared between 490 patients with hepatitis C and 167
with B virus infections. J Med Virol. 2006;78:459–465.
17.
Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of
hepatitis B and C virus infections on the natural history of compensated cirrho-sis: a
cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886–2895.
18.
Toshikuni N, Izumi A, Nishino K, et al. Comparison of outcomes between patients
with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J
Gastroenterol Hepatol. 2009;24:1276–1283.
19.
Bruno S, Zuin M, Crosignani A, et al. Predicting mor-tality risk in patients with
compensated HCV-induced cirrhosis: a long-term prospective study. Am J
Gastroenterol. 2009;104:1147–1158.
20.
Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated
cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology.
2006;43:1303–1310.
21.
Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol.
2007;5(6):453–63.
22.
Pawlotsky et al. Gastroenterology 2007;132:
23.
Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, et al.
Development of novel therapies for hepatitis C. Antiviral Res. 2010;86(1):79–92.
24.
Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new
insights into hepatitis C virus RNA replication. J Biol Chem. 2006;281(15):9833–6.
25.
Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, et al. A quantitative
test to estimate neutral-izing antibodies to the hepatitis C virus: cytofl uorimet-ric
assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci
USA. 1996;93(5):1759–63.
26.
Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, et al. Interaction of
hepatitis C virus-like particles and cells: a model system for studying viral binding
and entry. J Virol. 2002;76(18):9335–44.
27.
Sen GC. Viruses and interferons. Annu Rev Microbiol.2001;55:255–81.
28.
Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination
treatment of chronic
29.
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of
hepatitis C: an update. Hepatology. 2009;49(4):1335–74
30.
Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top
Microbiol Immunol 2013;369:113-142.
31.
Gish RG, Meanwell NA.The NS5A replication complex inhibitors:difference
makers?Clin Liver Dis 2011;15:627-639.
32.
Gao M,Nettles RE,BelemaM,et al.Chemical genetics strategy identifies an HCV NS5A
inhibitor with a potent clinical effect. Nature2010;465:96-100.
33.
Asselah T.NS5A inhibitors:a new breakthrough fort he treatment of chronic hepetitis
c.J Hepatol 2011;54:1069-1072.
Kronik HCV Enfeksiyonunda Antiviral Tedavinin Amaçlarý
